12:37 PM
 | 
Oct 12, 2017
 |  BC Extra  |  Clinical News

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859) to treat coronary heart disease (CHD). Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor.

Although anacetrapib met...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >